SEC Investigates Elan Over Disclosures of Clinical Trial Data and Side Effect Reports
This article was originally published in The Pink Sheet Daily
At issue: July 2008 reports of PML cases linked to Tysabri and key trial data for its Alzheimer's medication; Wyeth also gets a subpoena.
You may also be interested in...
The three-way drama heads toward a resolution -- if Biogen Idec accepts Elan's moves.
Biogen Idec's lawyers took heat all day Thursday from a federal judge, but in the end she ruled in their favor. Now, Elan has 23 days to fix the breach.
Following the release of lackluster Phase II efficacy data on bapineuzumab in Alzheimer’s disease patients, talk of Wyeth as a takeover target resurfaces.